New treatment for MOG antibody disease using nanoparticles
Official title: Novel immunotherapy against MOG antibody disease
Funded at Evoq Therapeutics, INC. · NIH-11007654 · Data updated 2026-11-12
This study is testing a new treatment for MOG antibody disease that uses tiny particles to help your immune system learn to tolerate the disease better, with the hope of providing a safer option than current medications like steroids.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Evoq Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project start | July 15, 2022 |
| Project end | June 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $1,000,000 |
| NIH project number | 9R44TR005293-02 |
| Project ID | NIH-11007654 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with MOG antibody disease who are experiencing symptoms such as vision loss or spinal cord damage.
✕Less likely to help
Patients with other neurological disorders not related to MOG antibody disease may not benefit from this research.
What this research studies
This research focuses on developing a novel immunotherapy for Myelin oligodendrocyte glycoprotein (MOG) antibody disease, a rare neurological disorder. The approach involves using synthetic high-density lipoprotein NanoDiscs to deliver specific antigen peptides to lymph nodes, aiming to induce immune tolerance and modify the disease. Current treatments involve steroids and immunosuppressants, which can have significant side effects, highlighting the need for safer, targeted therapies. The research builds on promising preliminary data from animal models that suggest this method could effectively treat MOGAD.
Why it matters
Potential benefit: If successful, this research could provide a safer and more effective treatment option for patients with MOG antibody disease.
How similar studies have gone: Other research has shown success with nanoparticle-based therapies in autoimmune diseases, indicating potential for this novel approach.
Where this research is happening
-
Evoq Therapeutics, INC.
Ann Arbor, United States Active
Researchers
- Principal investigator: Daniel, Weston — Evoq Therapeutics, INC.
- Study coordinator: Daniel, Weston
Related research
Other NIH-funded projects on the same topics.
-
Boosting immune response to fight cancer
This study is exploring a new way to help your immune system better fight cancer by tweaking certain cells in your body, and it aims to improve treatment for people with advanced cancer.
-
A center focused on immunotherapy for pediatric cancers.
This study is exploring new ways to use the body's immune system to fight childhood cancers, aiming to create better treatments for kids whose cancers haven't responded well to standard therapies.
-
Algorithms to find HLA-E neoantigens for cancer immunotherapy
Aims to develop computer methods to discover tumor-specific targets presented by HLA-E to guide new T cell therapies for cancer.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
How CRISPR-based gene activation could shape immunotherapy responses in clear cell cancers
A research project at Stanford is using CRISPR-based gene activation to understand why some clear cell ovarian and kidney cancers respond to immunotherapy while others do not.
-
Hybrid biomaterial system to boost immunotherapy for rheumatoid arthritis
A new, patient-facing immunotherapy approach uses specialized particles to retrain the immune system to calm RA in adults.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.